HK1162483A1 - 抑制激酶通路的組合物和方法 - Google Patents

抑制激酶通路的組合物和方法

Info

Publication number
HK1162483A1
HK1162483A1 HK12102835.1A HK12102835A HK1162483A1 HK 1162483 A1 HK1162483 A1 HK 1162483A1 HK 12102835 A HK12102835 A HK 12102835A HK 1162483 A1 HK1162483 A1 HK 1162483A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
compositions
methods
jak pathway
jak
Prior art date
Application number
HK12102835.1A
Other languages
English (en)
Inventor
Somasekhar Bhamidipati
Hui Li
Rajinder Singh
Vanessa Taylor
Jeffrey Clough
Darren Mcmurtrie
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of HK1162483A1 publication Critical patent/HK1162483A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102835.1A 2008-12-23 2012-03-21 抑制激酶通路的組合物和方法 HK1162483A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14060408P 2008-12-23 2008-12-23
US12/645,349 US8268851B2 (en) 2008-12-23 2009-12-22 Compositions and methods for inhibition of the JAK pathway
PCT/US2009/069480 WO2010075558A2 (en) 2008-12-23 2009-12-23 Compositions and methods for inhibition of the jak pathway

Publications (1)

Publication Number Publication Date
HK1162483A1 true HK1162483A1 (zh) 2012-08-31

Family

ID=42266455

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102835.1A HK1162483A1 (zh) 2008-12-23 2012-03-21 抑制激酶通路的組合物和方法

Country Status (7)

Country Link
US (2) US8268851B2 (zh)
EP (1) EP2370415B1 (zh)
JP (1) JP5485294B2 (zh)
CA (1) CA2745901C (zh)
ES (1) ES2583642T3 (zh)
HK (1) HK1162483A1 (zh)
WO (1) WO2010075558A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP2009528295A (ja) * 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US8268851B2 (en) * 2008-12-23 2012-09-18 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2014091265A1 (en) * 2012-12-11 2014-06-19 Aurigene Discovery Technologies Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
IN2013MU02611A (zh) 2013-08-07 2015-06-12 Cadila Healthcare Ltd
EP3206691B1 (en) * 2014-10-14 2018-09-19 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
US10300240B2 (en) 2015-05-07 2019-05-28 Aladdin Dreamer, Inc. Lucid dream stimulator, systems, and related methods
US9737683B2 (en) 2015-05-07 2017-08-22 Aladdin Dreamer, Inc. Lucid dream stimulator, systems, and related methods
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2020257495A1 (en) * 2019-06-18 2020-12-24 Purdue Research Foundation Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
DK2089369T3 (da) * 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8268851B2 (en) 2008-12-23 2012-09-18 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway

Also Published As

Publication number Publication date
US8268851B2 (en) 2012-09-18
ES2583642T3 (es) 2016-09-21
WO2010075558A2 (en) 2010-07-01
US20120301486A1 (en) 2012-11-29
US20100158921A1 (en) 2010-06-24
CA2745901A1 (en) 2010-07-01
CA2745901C (en) 2017-03-14
EP2370415A4 (en) 2012-09-12
EP2370415B1 (en) 2016-04-20
WO2010075558A3 (en) 2010-11-04
EP2370415A2 (en) 2011-10-05
JP5485294B2 (ja) 2014-05-07
JP2012513480A (ja) 2012-06-14
US8420659B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
HK1163076A1 (zh) 抑制 途徑的組合物和方法
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
ZA201300388B (en) Compositions and methods for inhibition of the jak pathway
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
IL187257A0 (en) Compositions and methods for inhibition of the jak pathway
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
HK1162483A1 (zh) 抑制激酶通路的組合物和方法
IL199941A0 (en) Compositions of stable tiacumicins
HK1215037A1 (zh) 流感抑制組合物和方法
EP2370815A4 (en) ANTI-INFLAMMATORY COMPOSITIONS AND RELATED METHODS
EP2361087A4 (en) INFLAMMATORY COMPOUNDS AND COMPOSITIONS THEREFOR
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201223